[D-Leu-4]-OB 3Alternative Names: OB 3
Latest Information Update: 20 Jan 2003
At a glance
- Originator Nonindustrial source
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 22 Mar 2001 Preclinical development for Obesity in USA (Unknown route)